The first Alzheimer’s therapy in the EU to ensure effective implementation • news • onvista

AMSTERDAM (dpa-AFX) – The European Arzneimittel-Behörde EMA has received approval for the first Alzheimer’s therapy in the EU, which abzielt on the zugrunde liede Krankheitsprozesse. The management of the antikörpers Lecanemab will be treated by a better treatment (thought and thought flow) or by Demenz in one of the Alzheimer-Krankheit stadiums.

It is possible that there is a problem: the Empfehlung-lautet, the drug for Alzheimer’s patients, which is now one or another copy of ApoE4, is one of the best forms for the protein apolipoprotein E. It is the best way to achieve the best results: Schwellungen and Blutungen in the device as in people with ApoE4 copies. Other Alzheimer’s therapies now treat the symptom of the disease.

Beim ersten Antrag noch abgelehnt

The one for the Zulassung sister EU Kommission follows the Votum der Behörde. Hersteller von Lecanemab since the Pharmaunternehmen Eisai (Japan) and Biogen (USA). In July, the EU Arzneimittelbehörde hates a Zulassung noch abgelehnt: The risks that the Antikörpers will take will be higher if the positive Wirkung, hieß es. The medicine counter is malfunctioning.

The anti-newspaper, which has had a trade name in the US since 2023, is the protein fragment beta-amyloid (Aß) derived from the air. “Amyloid is a serious factor in the beginning of a cascade of neuronal pathological changes in behavior,” says Jörg Schulz von der Uniklinik Aachen, Speaker of the Committee “Demenz und Kognitive Störungen” of the German Society for Neurology (DGN).

Nur im frühen Stadion usedbar

In Germany, one million people are affected by Alzheimer’s disease. When the contraceptive is no longer symptomatic, the fortress of the disease is completely compromised. Empfohlen is now for those affected in the Erkrankung stadium.

Verabreicht with the antikörper all two weeks during an intravenous infusion, which is brought to your attention. Weighing the microblutungen and treating the treatment will control the regular therapies per nuclear spin (MRT).

Fachleute wie Frank Jessen from the German Center for Neurodegenerative Diseases (DZNE) in Cologne, where the drug is found relatively quickly in Germany, is available. It all still takes a while, but it is a way to get a positive and responsible outcome from the therapy. Jessen has never had any problems with it, but one of the things the drug does is help you lose weight. “Weil der Druck von Patienten hoch ist. Viele sagen auch: Ich zahle das sofort self in eigener Tasche.”/kll/DP/ngu